We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-9.45%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.13B
AUM Growth
-$263M
(-19%)
Cap. Flow
-$67.3M
Cap. Flow
% of AUM
-5.93%
Top 10 Holdings %
Top 10 Hldgs %
53.9%
Holding
81
New
2
Increased
39
Reduced
9
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$23.3M |
| 2 |
Bioventus
BVS
|
+$12.1M |
| 3 |
Prothena Corp
PRTA
|
+$7.77M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$7.75M |
| 5 |
SI-BONE Inc
SIBN
|
+$7.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$60M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
+$27.4M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$18.6M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$15.2M |
| 5 |
LITS
Lite Strategy Inc
LITS
|
+$13.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.11% |
| 2 | Communication Services | 6.42% |
| 3 | Energy | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
26
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.8M | 1.31% |
116,869
-164,832
| -59% | -$18.6M |
|
27
Sutro Biopharma
STRO
$401M
| $13.7M | 1.21% |
167,250
-57,409
| -26% | -$5.46M |
|
28
OrthoPediatrics
KIDS
$519M
| $13.6M | 1.2% |
252,086
+14,701
| +6% | +$751K |
|
29
Crinetics Pharmaceuticals
CRNX
$8.84B
| $12.8M | 1.13% |
582,767
+309,971
| +114% | +$6.27M |
|
|
30
Bioventus
BVS
$892M
| $12.7M | 1.12% |
+901,525
| New | +$12.1M |
|
31
OptimizeRx
OPRX
$114M
| $12.5M | 1.1% |
330,546
+16,777
| +5% | +$743K |
|
|
NGM
32
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $12.5M | 1.1% |
816,653
+245,755
| +43% | +$3.83M |
|
33
NeoGenomics
NEO
$1.96B
| $9.79M | 0.86% |
805,958
+42,051
| +6% | +$885K |
|
34
MaxCyte
MXCT
$112M
| $9.24M | 0.81% |
1,321,406
+89,129
| +7% | +$609K |
|
35
Pfizer
PFE
$143B
| $7.62M | 0.67% |
147,235
+2,738
| +2% | +$142K |
|
36
BioMarin Pharmaceuticals
BMRN
$11.6B
| $7.18M | 0.63% |
93,082
-34,703
| -27% | -$2.9M |
|
37
Genmab
GMAB
$17.7B
| $5.86M | 0.52% |
161,913
+2,966
| +2% | +$102K |
|
|
TPTX
38
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $5.6M | 0.49% |
208,630
-340,996
| -62% | -$11.5M |
|
39
Mirum Pharmaceuticals
MIRM
$6.46B
| $4.74M | 0.42% |
+215,039
| New | +$4.39M |
|
|
AKU
40
DELISTED
Akumin Inc
AKU
| $4.12M | 0.36% |
3,710,385
+43,737
| +1% | +$54.3K |
|
|
NARI
41
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $4.11M | 0.36% |
45,379
+832
| +2% | +$68.1K |
|
|
ABCM
42
DELISTED
Abcam PLC
ABCM
| $4.09M | 0.36% |
223,386
+4,101
| +2% | +$72.6K |
|
|
SIEN
43
DELISTED
Sientra, Inc.
SIEN
| $3.97M | 0.35% |
178,936
+18,101
| +11% | +$496K |
|
44
Simulations Plus
SLP
$369M
| $3.9M | 0.34% |
76,453
+1,430
| +2% | +$61.4K |
|
|
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.72M | 0.33% |
45,205
-9,819
| -18% | -$1M |
|
46
Pliant Therapeutics
PLRX
$64.4M
| $2.88M | 0.25% |
411,328
+24,432
| +6% | +$249K |
|
|
LITS
47
Lite Strategy Inc
LITS
$32.8M
| $2.73M | 0.24% |
226,252
-334,619
| -60% | -$13.1M |
|
|
LHCG
48
DELISTED
LHC Group LLC
LHCG
| $2.61M | 0.23% |
15,500
+281
| +2% | +$37.6K |
|
|
MIRO
49
DELISTED
Miromatrix Medical Inc. Common Stock
MIRO
| $2.03M | 0.18% |
512,307
+24,215
| +5% | +$90.2K |
|
50
The Joint Corp
JYNT
$118M
| $2M | 0.18% |
56,498
+1,046
| +2% | +$48.4K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, First Light Asset Management held 81 positions worth $1.13B, down 19% from $1.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
First Light Asset Management withdrew a net $67.3M in Q1 2022, closing 6 positions and reducing 9 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $60M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Communication Services and Energy.
Against the trend, First Light Asset Management opened a new position in Bioventus worth $12.7M.
- First Light Asset Management's largest Q1 2022 buy was Bioventus: 901,525 shares worth $12.7M.
- First Light Asset Management added most to AtriCure in Q1 2022, an estimated $23.3M increase.
- First Light Asset Management's biggest Q1 2022 reduction was Intersect ENT, Inc, cutting an estimated $27.4M.
- First Light Asset Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $60M.
- First Light Asset Management's ten largest holdings make up 54% of its $1.13B portfolio in Q1 2022.
- First Light Asset Management opened 2 new positions and closed 6 in Q1 2022.
- First Light Asset Management's portfolio value fell 19% quarter-over-quarter to $1.13B.
Based on First Light Asset Management's 13F filing for Q1 2022, filed 13 May 2022.